Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Sr VP & General Manager | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 12,400 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 8,500 · Balance 12,400 F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 19, 2025 16:42 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123639 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,400 Underlying: Common shares · 8,500 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month) Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 14:28 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111570 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Underlying: Common shares · 1,500 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month). F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 18:09 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098497 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common shares · 40,000 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month). Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:59 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080992 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common shares · 4,200 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 00:52 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001213900-22-072924 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr. VP & General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common shares · 4,200 shares Expires 2027-11-13 F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| November 14, 2022 Filed Nov 19, 2022 00:36 UTC Amendment | InMed Pharmaceuticals Inc. INM · Entity 8139 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001213900-22-073946 · ownership.xml · derivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: Common shares · 4,200 shares Expires 2027-11-13 F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer. F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer. F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant. F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer. Read SEC document |
| January 06, 2022 Filed Jan 6, 2022 23:40 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 8,500 | $1.26 | $10,710.00 |
DisclosureSEC source: 0001213900-22-001005 · ownership.xml · nonDerivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,595 Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 00:22 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 8,093 | $1.33 | $10,736.17 |
DisclosureSEC source: 0001213900-21-068212 · ownership.xml · nonDerivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,095 Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 20:33 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Stock | 5,000 | $1.37 | $6,845.00 |
DisclosureSEC source: 0001213900-21-059271 · ownership.xml · nonDerivative · entry 1 Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,002 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.